Prostate cancer and hereditary risk: A doctor explains the connection

Some genetic mutations linked to breast cancer also can affect men, but in a different way. A urologist explains the connection

2:56 PM

Author | Jessica Webster Sendra

Michigan Medicine

This article was published on March 1, 2017 and was updated on September 4, 2026.

Thanks to Angelina Jolie and Christina Applegate, many are now aware that women with certain hereditary genetic mutations have an increased risk of breast cancer.

What you might not know, though, is that some of those same genetic mutations — and a handful of others — are linked to aggressive prostate cancer in men.

Doctors are seeing more advanced cases of prostate cancer in recent years, and PSA screening as been declining in recent years.

While the change in PSA screening means fewer men are receiving unnecessary treatment, others might have less of an opportunity to catch aggressive cancer at an early stage.

That's why it's important for men who are at an increased risk of developing prostate cancer to have access to a dedicated early detection program.

The Weiser Center for Prostate Cancer’s Prostate Cancer Risk Clinic provides exactly this program.

It's one of the few clinics in the country where men with a genetic predisposition to prostate cancer have access to a dedicated prostate cancer screening strategy.

Urologic oncologist Todd Morgan, M.D., co-director of the Weiser Center, spoke about what all men need to know.

Is there a connection between hereditary risk of breast cancer and the risk of prostate cancer?

Morgan: Yes. Let's say a woman has a strong family history of breast cancer, so she gets tested and finds out that she has a BRCA2 mutation.

We have a very robust high risk breast cancer clinic for that woman, providing counseling around her cancer risk, detection strategies and options for cancer prevention.

That's something people have known for years — BRCA1 and BRCA2 predispose to breast cancer.

Once a woman has identified that she has the mutation, she will need very careful screening under the care of some type of clinic like we have here.

That woman's sister would likely also go in for genetic testing at this point to find out if she, too, is at risk.

Here's the problem, though: Her brother historically might not necessarily be tested because BRCA1 and BRCA2 have always been linked to breast cancer.

Although men do occasionally get diagnosed with breast cancer, it's pretty rare.

But more and more people are realizing that BRCA mutations predispose to other cancers that impact men, like prostate cancer.

And, in fact, it's not just that they'll be predisposed to prostate cancer: BRCA2 mutations predispose to a more aggressive type of prostate cancer, but these cancers also may be more responsive to certain types of therapies.

And so that man might get referred from that high-risk breast clinic to a genetics clinic here, where he can get tested for that mutation.

If it's determined that he shares the same genetic mutation as his sister, he should begin very careful screening.

Are there other genetic mutations that put men at a higher risk for prostate cancer?

Morgan: Another example would be Lynch syndrome, which predisposes to colorectal cancer as well as several other cancers.

Over the last 10 years, we've realized that men with one of the mutations that predisposes to Lynch syndrome are also predisposed to aggressive prostate cancer. But the word hasn't really gotten out.

Other genetic mutations that appear to put men at higher risk for prostate cancer include Li-Fraumeni syndrome (p53), ATM, PALB2, CHEK2, RAD51D, ATR, NBN, GEN1, RAD51C, MRE11A, BRIP1 and FAM175A.

Why is it important for men with a family history to be tested for genetic mutations?

Morgan: Primary care doctors are no longer consistently recommending routine prostate cancer screening to their patients, which seems to be sending the message that men don't need to worry about prostate cancer.

The reality is that prostate cancer is the second leading cause of cancer deaths in men in the United States.

Men who have inherited mutations are much more likely to have aggressive prostate cancer.

We know that treatment of aggressive prostate cancer works and prevents death and suffering from prostate cancer.

That's what this is about more than anything else: preventing death and suffering from prostate cancer.

For more information, call the Cancer AnswerLine at 800-865-1125.


More Articles About:

Cancer Care Prostate Cancer BRCA gene Genetic Testing Cancer: Cancer Types
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

In This Story

Todd Morgan

Todd M Morgan, MD

Professor

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Microscope images of prostate cancer cells
Health Lab

New drug combination may help treat advanced prostate cancer

University of Michigan researchers found that combining BET bromodomain and DNMT inhibitors may slow the growth of treatment-resistant prostate cancer by targeting transdifferentiated tumors.
Stephen and Faith Brown standing together next to a huge bell at the top of Burton Memorial Tower.
Philanthropy News

Long friendship inspires urology resident fund

U-M alumni Stephen and Faith Brown have created a fund to expand research and travel opportunities for urology residents in the U-M Medical School.
close up of cells blue purple pink
Health Lab

Researchers create new path to target hard-to-drug prostate cancer protein

University of Michigan researchers have identified a specific pocket within ERG, a driver of prostate cancer, and have developed a small molecule probe, called PBITE-1, that can bind to it.
News Release

Rogel research team receives $3. 2 M grant to cascade genetic testing to relatives

A team of researchers based at the University of Michigan Rogel Cancer Center and Stanford University received $3.2 million from the National Cancer Institute for a clinical trial to help patients with a hereditary-based cancer diagnosis extend genetic testing to at-risk relatives.
purple yellow red cells up close
Health Lab

Study explains how colorectal cancer cells maintain high iron levels

How colorectal cancer cells maintain high iron levels, according to Michigan Medicine research.
A nurse leans over the bed of a patient who is covered up and wearing a neck brace. They appear to be having a pleasant conversation.
Philanthropy News

Giving with gratitude: planned gifts support nursing, research, and patient care

Retired businessman and Detroit Tigers fan Paul Hansen has created three planned gifts to support prostate cancer research, nursing scholarship support, and adult cerebral palsy research at Michigan Medicine.